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1. Introduction 
In recent years there has been important advancement in our knowledge of iron metabolism 
regulation that also has implications for understanding the physiopathology of some human 
disorders like beta-thalassemia and other iron overload diseases.  In fact, progressive iron 
overload is the most salient and ultimately fatal complication of beta-thalassemia. Iron 
deposition occurs in visceral organs (mainly in the heart, liver and endocrine glands), 
causing tissue damage and ultimately organ dysfunction and failure. Both transfusional iron 
overload and excess gastrointestinal absorption are contributory. Paradoxically, excess 
gastrointestinal iron absorption persists despite massive increases in total body iron load. 
However, little is known about the relationship among ineffective erythropoiesis, the role of 
iron-regulatory genes, and tissue iron distribution in beta-thalassemia. The focus of this 
chapter is an update about iron homeostasis and erythroid differentiation with a particular 
attention to the molecular mechanisms of iron homeostasis deregulation in thalassemia and 
to the GDF15-BMP-Hepcidin-Ferroportin regulatory pathway in order to understand the 
contribution to iron overload. The chapter describes evidences for these relationships and 
discusses how recent discoveries on iron metabolism and erythropoiesis could lead to new 
therapeutic strategies and better clinical care of these diseases, thereby yielding a much 
better quality of life for the patients.  
2. Overall view on erythroid cells differentiation and importance of iron 
homeostasis 
Iron homeostasis depends on a coordinated regulation of molecules involved in the import 
of this element and those exporting it out of the cells. In some cell types, such as erythroid 
cells, iron import mechanisms are highly expressed, thus allowing massive iron uptake 
(Pietrangelo, 2002; Testa et al.,1995). Excessive iron, however, may be toxic for these cells, 
particularly in view of its capacity to generate superoxide radicals and H2O2, which may 
freely diffuse into the nucleus resulting in cell damage (Karthikeyan, 2002) and it seemed 
therefore of interest to investigate whether erythroid cells possess specific mechanisms for 
iron export. Within the hematopoietic differentiation, the maintenance of iron homeostasis is 
essential for erythroid cells and macrophages. Erythroid cells need to incorporate very high 
amounts of iron to support the continued synthesis of heme and hemoglobin, while the 
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macrophage cells play a key role in iron storage and recycling (Ponka, 1997; Testa et al.,1993; 
Testa, 2002). Human erythropoiesis is a dynamic complex multistep process that involves 
differentiation of pluripotent hematopoietic stem cells (HSCs) and early multipotent 
progenitors (MPP) to generate committed erythroid precursors, the erythroblasts, which then 
give birth to mature erythrocytes, i.e. the red blood cells (RBCs) (Orkin & Zon, 2008; Palis, 
2008; Tsiftsoglou et al., 2009; Weissman, 2000). Briefly, the early erythroid progenitors (BFU-E, 
burst-forming units-erythroid) differentiate into late colony-forming units erythroid (CFU-E) 
and proerythroblasts followed by a progressive wave of erythroblast maturation in 
polychromatic and orthochromatic erythroblasts coupled with a gradual increase of erythroid-
specific markers (Fig.1). As the hematopoietic process progresses from the early stages into 
erythroid cell maturation, cells gradually lose their potential for cell proliferation and become 
mature enucleated cells(Fig.1). Mature erythrocytes are biconcave disks without mithocondria 
and other organelles but full of hemoglobin able to bind and deliver O2 (Ingley et al., 2004; 
Koury et al., 2002; Stamatoyannopoulos, 2005; Tsiftsoglou et al., 2009). The hematopoietic 
differentiation is a highly complex system in which, from a pool of totipotent stem cells, 
originate all the cells of peripheral blood (Golde, 1991; Metcalf, 1989; Orkin, 1996; Smith, 2003). 
The blood has a very important role in the functions of the organism from the earliest 
moments of its development, so that during embryonic life the various stages of the 
hematopoietic process alternate at different sites according to the different stages of 
development (Emerson et al., 1989). The embryonic→fetal hematopoiesis is characterized by 
three fundamental periods of activity progressively involving the yolk sac, liver and bone 
marrow. The first period, during which hematopoiesis is localized at the yolk sac, begins 
between the 14th and 19th days of embryonic life and continues until the completion of 3rd 
month (Emerson et al., 1989). Starting from the third month, the second phase of 
hematopoiesis takes place in the liver where it reaches its maximum during the 3rd-4th month 
and remains active until a few weeks before birth, when the definitive hematopoiesis (third 
phase) is concentrated only in the bone marrow and it will continue throughout adult life 
(Emerson et al., 1989). In this system of hematopoietic differentiation four compartments may 
be identified: stem cells and the progenitors (cellular compartments), precursors and mature 
elements of circulating blood (maturation compartments).  Hematopoietic stem cells are 
characterized by the ability to self-renew (i.e. to generate other totipotent stem cells) and 
differentiate into hematopoietic progenitor cells. Stem cells also show the important property 
to remain for long time in a state of quiescence during adult life (Domen,1999;Metcalf,1989; 
Orkin, 1996; Smith, 2003). Primitive progenitors are able to generate blast colonies (CFU-B), the 
progenitors of high proliferative potential (HPP-CFC, colony-forming cells that power high-
proliferative), and finally the multipotent progenitors that are still capable of generating mixed 
colonies, belonging to the different types of hematopoietic differentiation: erythroid, 
granulocyte, monocyte, and megakaryocytic (the CFU-GEMM) (Orkin, 1996; Ogawa, 1993; 
Grover, 1994). Mature progenitors are committed to the differentiation towards a singular 
hematopoietic lineage and are functionally defined as early burst forming units (BFUs) or 
more differentiated colony forming units (CFUs): erythroid progenitors are BFU-E and CFU-E; 
granulocytic-macrophagic progenitors are CFU-GM, CFU-G and CFU-M; finally 
megakaryocitc progenitors are BFU-Mk and CFU-Mk (Grover, 1994; Ogawa, 1993; Orkin, 1996; 
Smith, 2003). The survival, proliferation and differentiation of hematopoietic stem and 
progenitor cells are regulated by a complex network of hematopoietic growth factors 
collectively known as colony stimulating factors (CSFs), interleukins (ILs) or hemopoietins that 
are released from accessory cells such as fibroblasts, macrophages, lymphocytes and 
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endothelial cells. Depending on their mechanism of action during hematopoietic 
differentiation, these factors can be classified into three categories: the first category includes 
growth factors that exert their action at the earliest stages of hematopoiesis, e.g. the c-kit 
receptor ligand (KL) or stem cell factor (SCF) (Bernstein,1991), FLT-3 ligand (FL) (Gabbianelli, 
1995;Lyman,1994;), the basic fibroblast growth factor (bFGF) (Berardi, 1995; Gabbianelli, 1990) 
and interleukin-6 (IL-6) [Leary, 1988]; in the second category are growth factors acting as 
multilineage, whose prototypes are the IL-3 and GM-CSF that are able to stimulate primitive 
progenitors to proliferate and differentiate into all hematopoietic lineage (Metcalf, 1993); and 
finally in the third category are included the growth factors acting as unilineage, i.e. those that 
stimulate the differentiation and proliferation of a single lineage and include erythropoietin 
(EPO) [Fried, 1995; Krantz, 1991], the granulocytic growth factor (G-CSF) [Demetri & Griffin, 
1991], monocytic growth factor (M-CSF) [Sherr, 1990] and thrombopoietin (TPO) [Kaushanky 
et al., 1994]. These unilineage factors act on progenitors already moving towards 
hematopoietic lineage and promote the production of mature cells in the circulating blood, i.e. 
erythrocytes, neutrophils, eosinophils, monocytes/macrophages and megakaryocytes. During 
the hematopoietic differentiation, the maintenance of iron homeostasis is essential for 
erythrocytes and macrophages. Erythroid cells need to incorporate very high amounts of iron 
to support the continued synthesis of heme and hemoglobin, while the macrophage cells play 
a key role in the storage and recycling of iron (Testa et al., 1993; Testa, 2002; Tsiftsoglou,2009). 
During the differentiation of erythroid progenitors towards mature red cells the following 
morphologically recognizable stages can be distinguished: 1) the earlier stage of 
proerythroblast, that presents a nucleus relatively large in respect to the cytoplasm, and one or 
two nucleoli; 2) the more advanced basophilic erythroblast, characterized by a reduced cellular 
diameter, a nuclear volume reduced more rapidly than the cytoplasm, and a cytoplasm 
uniformly basophilic; 3) the polychromatophilic erythroblast, that shows the initial 
condensation of the nucleus, nucleoli no longer visible and the cytoplasm with acidophilic 
areas; 4) the orthochromatic erythroblast, with a nucleus:cytoplasm ratio of approximately 1:4, 
nucleus darker and subject to pyknotic degeneration, and cytoplasm slightly pink as a 
consequence of the progressive increase in hemoglobin concentration; 5) and finally the 
reticulocyte that has lost its nucleus and, through the complete degradation of ribosomes and 
mitochondria, proceeds to the transformation in mature erythrocyte (Grover, 1994; Loken et 
al., 1987; Okumura et al., 1992; Orkin, 1996) (Fig.1). In adult mammalian bone marrow 
erythroblasts are always associated to the erythroblastic islets, that represent the drive 
amplification stage anatomy of erythropoiesis and consists of 1 or 2 histiocytic crown cells 
surrounded by erythroblasts at all stages of maturation. The histiocytes have thin cytoplasmic 
extensions that insert between erythroblasts suggesting that factors of nutrition can be 
provided by the histiocytic cell, centrally located, to the peripheral maturing erythroblasts 
(Grover, 1994; Orkin, 1996). The circulating red cell mass is maintained constant by a 
homeostatic mechanism regulating erythropoiesis, based on an erythropoietic stimulus which 
ensures that, under physiological conditions, the production of red blood cells equals their 
destruction. Moreover, in response to hypoxia, hemorrhage or hemolysis, this stimulus causes 
increase in the production of red blood cells (Ponka, 1997). The most important factor involved 
in the control of erythropoiesis is erythropoietin, but other substances, particularly hormones, 
contribute to the regulation of this process [Fried, 1995; Ponka, 1997]. Transferrin comes out 
from the bone marrow sinusoids using ample fenestrature exits, and binds to surface receptors 
carried by erythroblasts. The iron transferred from transferrin and transported to the 
mitochondria is reduced from Fe3+ to Fe2+ and then inserted into protoporphyrin IX by 
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tetrapyrroles heme synthetase (Heme synthetase HS) for the synthesis of heme (Ponka, 1997; 
Testa et al., 1993; Testa, 2002). The reticuloendothelial system is a functional unit that includes 
cells having heterogeneous histologically different identities and a widespread distribution 
throughout the body, which share the common property of phagocytic activity, e.g. 
endothelial cells of blood capillaries of liver, spleen, bone marrow and lymph nodes, tissue 
and circulating macrophages (Andrews, 2000; Ponka, 1997). Reticuloendothelial system is the 
most important source of iron that enters the blood compartment. The flow of iron from 
reticuloendothelial plasma is unidirectional, as the reticuloendothelial cells are not able to pick 
up the metal from transferrin, but receive only hemoglobin or ferritin iron (Ponka, 1997; 
Andrews, 2000).Senescent erythrocytes at the end of their life (approximately 120 days) are 
phagocytized by endothelial cells and represent the largest source of iron entering the 
reticuloendothelial system. About 85% of the iron that enters the reticuloendothelial cells is 
promptly transferred to plasma transferrin and the remaining 15% is stored as intracellular 
ferritin, and transferred to plasma much more slowly [(Andrews, 2000; Grover, 1994; Ponka, 
1997). 
 
Fig. 1. Pathway of the erythropoiesis from progenitors to mature cells. Different stages are 
indicated: hematopoietic stem cell (HSC), burst-forming unit erythroid (BFU-E), colony-
forming unit erythroid (CFU-E), proerythroblast (ProE), basophylic (BasoE), polychromatic 
(PolyE) and orthochromatic erythroblast (OrthoE). Coloured bars indicate timing of FPN1 
alternative transcript expression (bottom) and hemoglobin synthesis referred to stages of 
erythropoiesis (bottom). 
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3. Iron acquisition by erythroid cells 
Most of the iron in the plasma is bound to transferrin, an 80-kDa  glycoprotein with 
homologous N-terminal and C-terminal iron-binding domains that is synthesized in the 
liver(De Domenico et al., 2008). Plasma transferrin has two important roles in iron 
physiology: first, the high iron-binding affinity of transferrin and the presence of a high 
concentration of apotransferrin (the iron-free form of transferrin) ensure that when iron 
enters plasma it is chelated , so limiting the ability of iron to generate toxic radicals; second, 
transferrin also directs iron towards cells that express transferrin receptors(De Domenico et 
al., 2008). Erythroid precursors require efficient iron uptake from Tf so that hemoglobin can 
be produced. TfR1 mediates erythroid iron acquisition, and its expression paralleles the 
maturation of erythroid progenitors (Hentze et al.,2004). The number of TfRs on erythroid 
cell, markedly higher than on other cell types (Sposi et al., 2000) is directly related to 
hemoglobin (Hb) production (Horton, 1983; Iacopetta et al., 1982; Nunez et al., 1977). In 
normal erythropoiesis, the hyperexpression of TfR1, starting from early erythroid HPC 
differentiation, is Epo-dependent and mediated via transcriptional and post-transcriptional 
mechanisms (Sposi et al., 2000). Both the number of TfRs present on the membrane and 
cellular ferritin concentration are regulated by intracellular iron level. Coordinate regulation 
of TfRs and ferritin is one of the most extensively studied mechanisms of post-
transcriptional control of gene expression. In response to iron deprivation, the cytoplasmic 
stability of TfR mRNA is increased and ferritin mRNA translation inhibited (Klausner et al., 
1993). As a consequence, enhanced iron uptake and diminished iron storage compensate for 
the lack of iron. The feedback regulation can be considered as a protective mechanism that 
prevents nutritional starvation and permits the biosynthesis of essential iron or heme-
containing proteins. Under conditions of high iron supply, when cells need to store excess 
iron in order to prevent adverse effects of iron overload, the regulatory balance is inversed: 
TfR mRNA decays more rapidly and ferritin translation is no longer inhibited(Klausner et 
al., 1993). After binding to its receptor, the complex of Fe(III)-transferrin-TfR1 is rapidly 
internalized by receptor-mediated endocytosis through clathrin-coated pits (De Domenico et 
al., 2008 ; Ponka et al,1998). Acidification of the endosome produces a conformational 
change in both transferrin-Fe(III) and TfR1 with the consequent release of iron (Bali et al., 
1991; De Domenico et al., 2008; Sipe & Murphy, 1991). The endosomal Fe(III) is converted 
into Fe(II) by a STEAP3, an erythroid-specific reductase (Ohgami et al., 2005). 
DMT1/Nramp2, a protons and Fe(II) co-transporter present in the endosomal membrane, 
transports iron into the cytosol (De Domenico et al., 2008; Gunshin et al., 2001). 
DMT1/Nramp2 is a member of the natural resistance-associate-macrophage protein 
(Nramp) family (Cellier et al., 1995). Several isoforms of the DMT1/Nramp2 mRNA are 
known, resulting from alternative splicing and/or the use of two alternative upstream 
promoter regions (Hubert & Hentze, 2002; Millot et al., 2009; Tabuchi et al., 2002). The 
isoform I is localized mainly at the apical site of the enterocytes and other epithelial cells 
whereas isoform II is found on the endosomal membrane of peripheral tissues and erythroid 
cells (Canonne-Hergaux et al., 2001; Millot et al., 2009). At acidic pH, apotransferrin remains 
bound to TfR1 and the complex is recycled to the cell surface (De Domenico et al., 2008). At 
the more neutral pH of plasma, apotransferrin dissociates from TfR1 and is free to bind iron 
and initiate further rounds of receptor-mediated endocytosis (De Domenico et al., 2008).  
www.intechopen.com
 
Iron Metabolism 
 
66
4. Iron utilization by erythroid cells 
Erythroblasts also handle large amounts of iron. In these cells, most of the iron leaving the 
endosome is then transported to the mitochondria for heme synthesis and iron-sulfur cluster 
assembly (Napier et al., 2005). Potentially, iron may be directly transported from endosome 
into mitochondria by a “kiss-and-run mechanism” through a direct contact between both 
organelles, effectively bypassing the cytosol (Sheftel et al., 2007).Mitoferrin (Mfrn1, 
SLC25a37), a protein belonging to the family of mitochondrial solute carrier proteins 
expressed in the inner mitochondrial membrane, is thought to be implicated in shuttling 
iron across mitochondrial membrane (Millot et al., 2009; Shaw et al., 2006). The zebra fish 
mutant frascati with a mutated Mfrn1 gene shows profound hypochromic anaemia due to 
defective iron uptake by mitochondria (Shaw et al., 2006). Mfrn1 has a paralogue in 
mammals, Mrfn2 that is ubiquitously expressed. Silencing of both Mrfn1 and Mrfn2 induces 
reduction in heme synthesis by 90% (Paradkar et al., 2009). Most of heme in the body is 
synthesized in erythroid cells, as a precursor to hemoglobin formation, although heme is 
also the prosthetic group of various types of proteins, such as cytosolic or mitochondrial 
cytochromes, catalase, peroxidase and NO synthase (Millot et al., 2009). The erythroid-
specific first enzyme of protoporphyrin IX synthesis,  5-aminolaevulinate synthase (ALAS), 
is encoded  by two different genes:  ALAS1 which is ubiquitously expressed and ALAS2, 
which is expressed only in erythroid cells (Furuyama et al., 2007). Regulation mechanisms 
differ widely between the two isoforms, i.e ALAS1 expression is negatively regulated by 
heme, whereas ALAS2 expression is only dependent on iron (Furuyama et al., 2007). 
Ferrochelatase, the last enzyme of the pathway, synthesizes heme from Fe(II) and 
protoporphyrin IX (PIX). Heme is then transported out of the mitochondria to be associated 
to globin chains and apocytochromes (Furuyama et al., 2007). Three molecules have been 
identified as possible mitochondrial heme exporters or transporters: the breast cancer 
resistance protein (ABCG2) (Jonker et al., 2002), the ABC-mitochondrial erythroid (ABC-me) 
transporter (Shirihai et al., 2000) and the feline leukemic virus subgroup C receptor 
(FLVCR)(Quigley et al., 2004). Heme export from mitochondria is thought to be mediated by 
ATP-Binding Cassette (ABC) transporters, i.e. ABCG2 and ABC-me (Shirihai et al., 2000), 
although the exact nature of the transporter has not been elucidated. FLVCR could be 
required for differentiation of erythroid precursors into colony forming units, potentially 
protecting cells against heme toxicity by exporting excess heme that can otherwise result in 
oxidative stress (Dunn et al., 2008; Quigley et al., 2004). However, the heme transporters 
responsible for heme release remain unclear. Another important function of iron in the 
mitochondria is to ensure the [Fe-S] cluster synthesis. It has been proposed that frataxin acts 
as a metabolic switch between [Fe-S] cluster and heme synthesis (Becker et al., 2002; Dunn et 
al., 2006). Frataxin expression is much decreased in the disease Friedreich’s ataxia, in which 
iron loading occurs in the mitochondria (Dunn et al., 2006; Puccio et al., 2001). The 
molecular form of this excess iron remains unknown, but it could be unbound iron or iron 
stored in mitochondrial ferritin or other proteins (Dunn et al., 2006). Ferritin mitochondrial 
(FtMt) mRNA does not contain IRE, contrary to the H and L ferritin mRNAs, and therefore 
the FtMt synthesis is not regulated by the IRE/IRP system (Drysdale et al., 2002; Levi et al., 
2001). The role of this FtMt is not fully elucidated but is thought to be a protective molecule 
against iron-mediated oxidative damage rather than an iron-storage molecule (Millot at al., 
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2009). Although erythroid cells consume large amounts of iron, they have to maintain safety 
mechanisms to avoid iron and/or heme excess. It can be stored in ferritin or exported by 
ferroportin. Additionally, erythroblasts also have the capacity to export excess heme by 
FLVCR (Keel et al., 2008). 
5. Iron- and haem-dependent regulation in erythroid cells 
Iron metabolism and cellular heme represent two of the most key regulators of 
erythropoiesis (Andrews, 2008; Nemeth et al., 2008; Tsiftsoglou et al., 2009). The principal 
source of iron for erythrocyte precursors is plasma iron-transferrin (Fe-Tf), whereas heme 
derives from plasma as well as “de novo” biosynthesis inside the mitochondria as 
protoporphyrin IX first and then as iron-protoporphyrin IX (heme) after incorporation of 
iron with ferrochelatase (Tsiftsoglou et al., 2009). Trafficking and storage of iron in the 
mitochondria is tightly regulated as excess free iron promotes the generation of harmful 
reactive oxygen species whereas an inadequate supply of iron prevents haemoglobin 
synthesis leading to microcytic hypochromic anaemia (Martin et al., 2006; Millot et al., 
2009). Cellular iron homeostasis is coordinately regulated posttranscriptionally by 
IRE/IRP system during erythroid differentiation. The analysis of IRP expression in 
hemopoietic cells provided some potentially interesting findings. It is well established 
that two different IRPs, IRP-1 and IRP-2, exist in mammalian cells (Henderson et al., 1993; 
Sposi et al., 2000). Both these proteins interact with the IRE sequence, six nucleotide loops, 
present in the certain mRNA 5′ or 3′ untranslated regions. The binding of IRP to ferritin 
mRNA results in translational block, while the binding to TfR mRNA results in mRNA 
stabilization (Sposi et al., 2000; Thomson et al., 1999). In spite of these similarities, 
however, IRP-1 and IRP-2 exhibit some important differences. In fact IRP-1 is related to 
mitochondrial aconitase, an enzyme of the Krebs cycle. Under high iron conditions IRP-1 
dissociates from the IRE and is converted to a cytoplasmic aconitase through insertion of a 
[4Fe-4S] cluster (Haile et al., 1992). IRP-2 shares 60% amino-acid homology with IRP-1, 
but differs having a 73-amino-acid insertion in its N-terminal region, which confers a 
sensitivity to degradation via the ubiquitin–proteasome pathway in iron loading 
conditions (Guo et al., 1995; Henderson et al., 1993). IRP-2 is unable to assemble a [4Fe-4S] 
cluster and thus lacks aconitase activity. IRP-1 and IRP-2 are differentially expressed in 
hemopoietic cells and their expression is modulated during differentiation/proliferation 
of these cells. Thus, during differentiation of Hemopoietic Progenitor Cells (HPCs) from 
progenitor cells to mature cells it was observed that, during the initial stages 
of hemopoietic cell differentiation both IRP-1 and IRP-2 mRNAs are induced in all 
hemopoietic lineages; however, at later stages of differentiation, IRP-2 is expressed in all 
hemopoietic lineages at different stages of differentiation/maturation, IRP-1 is selectively 
expressed only in erythroid cells, while its expression is lost in all the other hemopoietic 
lineages (Sposi et al., 2000). It is not clear whether both IRP1 and IRP2 contribute to 
stabilization of TfR1 mRNA but several lines of evidence suggest that IRP2 is the main 
iron-sensor in erythroid cells: i.e., heme deficiency stabilizes IRP2 whereas accumulation 
of free heme induces its ubiquitination and degradation by the proteasome (Ishikawa et 
al., 2005; Millot et al., 2009); IRP2 knock-out mice develop microcytic hypochromic 
anaemia with reduced TfR1 expression in bone marrow cells (Cooperman et al. 2005; Galy 
et al., 2005; Millot et al., 2009); primary erythroblasts deficient in Stat5 showed a reduction 
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in IRP2 expression, with a concomitant reduction in TfR1 mRNA and increasing of IRP1 
(Kerenyi et al., 2008). The observation that in differentiating erythroblasts, TfR1 mRNA 
stability and IRP mRNA-binding affinity are no longer modulated by iron supply, has 
recently challenged the implication of the IRE/IRP system in iron homeostasis regulation 
in erythroid cells (Schranzhofer et al., 2006). This would be in agreement with the so 
called “kiss-and-run” hypothesis (Ponka et al., 1997; Richardson et al., 1996). It suggests 
that during terminal erythropoiesis endosomes come into close vicinity/physical contact 
with mitochondria to directly shuttle iron into this organelle for heme synthesis without 
modulating the mRNA-binding activity of the IRPs (Ponka et al., 2002; Zhang et al., 2005). 
This dual mechanism contributes to maintaining the high flux of incoming iron available 
for heme synthesis rather than being sequestered into ferritin (Millot et al., 2009). The 
level of cellular heme is very critical in the regulation of erythropoiesis. Heme 
biosynthesis is increased dramatically during Epo-moderated erythropoiesis to meet extra 
demand for red blood cell production under hypoxic conditions or stress erythropoiesis 
(Tsiftsoglou et al., 2009). Heme is needed for the production of large number of 
hemoproteins involved in cell respiration, O2 tension sensing and metabolism (Tsiftsoglou 
et al., 2009). Heme is also needed to regulate the transcription of globin and nonglobin 
genes, because it has been found to regulate the action of transcription factors at nuclear 
level (Tsiftsoglou et al., 2009). Heme itself functions as a transcriptional regulator. It can 
induce heme oxygenase 1, HO-1, a molecule which reciprocally induces heme 
degradation (Huihui and Ginzburg, 2010). Heme strongly stimulates HO-1 expression by 
inhibiting the transcriptional repressor Bach 1. Binding of a heterodimer of the small maf 
transcription factor and Bach 1 to the multiple MARE (maf recognition element) sites in 
HO-1 enhancer represses HO-1 gene expression (Millot et al., 2009). It has been shown 
that HO-1 mRNA decreases following erythroid differentiation of Friend erythroleukemia 
cells, while mRNAs coding for the enzymes of the heme biosynthetic pathway increase 
(Millot et al., 2009; Fujita and Sassa, 1989). Heme non participating in hemoglobin 
synthesis results in a downregulation of IRP2 which reduces TfR1 expression on the cell 
surface and thus the amount of iron entering cells so preventing excess heme from 
accumulating in erythroid precursors (Huihui and Ginzburg, 2010; Ishikawa et al., 2005). 
In order to prevent excess globin synthesis, heme deficiency represses globin synthesis by 
activating a stress protein kinase named heme regulated inhibitor (HRI) which 
phosphorylates eIF2ǂ (McEwen et al., 2005; Millot et al., 2009). Finally heme export has 
also recently been demonstrated in erythroid precursors. It has been shown that the feline 
leukemia virus, subgroup C, receptor (FLVCR) could function as a heme exporter (Quigly 
et al., 2004; Taylor et al., 1999). FLVCR is a member of the family of MFS (major facilitator 
superfamily) proteins which transport small solutes across membranes by using the 
energy of ion-proton gradient (Millot et al., 2009; Taylor et al., 1999). The absence of 
FLVCR results in arrest of proerythroblast differentiation and apoptosis, likely due to 
heme toxicity, whereas FLCVR overexpression in mice results in a mild microcytic 
hypocromic anemia suggesting that it is needed to maintain heme and globin balance and 
avoid accumulation of free heme or excess globin in the cytoplasm (Huihui and Ginzburg, 
2010; Keel et al., 2008). In conclusion during erythroid differentiation the existence of an 
interplay of positive and negative feedback mechanisms maintains sufficient iron supply 
for heme synthesis and prevents formation or accumulation of heme in excess of globin 
chains. 
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6. Iron deficiency and anemia 
Under physiological conditions, there is a balance between iron absorption, iron transport 
and iron storage in the human body. Iron deficiency anemia may result from the interplay of 
three distinct risk factors: increased iron requirements, limited external supply and 
increased blood loss (Munoz et al., 2010). Likewise, inappropriately high levels of hepcidin 
expression lower plasma iron levels and cause anemia. In this context, the common acquired 
anemia of chronic diseases (ACD) and the genetic iron-refractory iron deficiency anemia 
(IRIDA) are the most interesting examples. Several physiopathological features contribute to 
the anemia of chronic diseases, also known as the anemia of inflammation: impaired 
proliferation of erythroid progenitors and blunted response to erythropoietin, reduced 
erythropoietin synthesis as well as reduced life span of red blood cells (Millot et al., 2009). 
The basis of the disorder is that inflammatory stimuli, such as those caused by bacterial 
infections, cause acute hypoferremia presumably in an attempt to limit the growth of 
bacteria by limiting iron (De Domenico et al., 2008; Schaible and Kaufmann, 2004). During 
inflammation IL-6 seems to be the major pro-inflammatory cytokine implicated in hepcidin 
activation through a Stat3 dependent signaling pathway, so allowing the identification of a 
link between iron homeostasis and inflammation (Millot et al., 2009; Wrighting and 
Andrews. 2006). Hypoferremia develops rapidly as a result of decreased macrophage iron 
release leading to iron-limited erythropoiesis. Increased cellular iron retention is the result 
of decreased levels of cell-surface ferroportin, which, in turn, results from sustained 
secretion of hepcidin (De Domenico et al., 2008). Low or undetectable levels of hepcidin are 
normally observed in patients with iron deficiency. On the contrary, patients with IRIDA 
show very low iron stores and microcytic anemia refractory to iron treatment in 
consequence of inappropriately high hepcidin levels. IRIDA is caused by mutations in 
TMPRSS6 (matriptase-2), a gene that encodes a protease that negatively regulates hepcidin 
expression (Du et al., 2008). Recently it has been observed that genetic variants in TMPRSS6, 
frequent in the general population, may modulate the ability to absorb iron and to 
synthesize hemoglobin for maturing erythroid cells (Andrews, 2009). Recent study suggest 
that TMPRSS6 normally acts to down-regulate hepcidin expression by cleaving membrane-
bound hemojuvelin, HJV, (Silvestri et al., 2008).     
7. Iron overload and hereditary hemochromatosis 
Hereditary hemochromatosis is an iron overload disease characterized by excessive body 
iron that causes tissue damage in the liver, pancreas and heart (Pietrangelo A, 2004).  
Currently four types have been identified in Caucasian populations: type 1 is the common 
form and is an autosomal recessive disorder of low penetrance strongly associated with 
mutations in the HFE gene ; type 2 (juvenile hemochromatosis) is autosomal recessive, of 
high penetrance with causative mutations identified in the HFE2 and HAMP genes; type 3 is 
also autosomal recessive with mutations in the TfR2 gene; type 4, or HFE4 (OMIM 606069), 
or ferroportin disease, is an autosomal dominant condition with heterozygous mutations in 
the ferroportin 1 (FPN1) gene (Worwood, 2005). FPN1(also known as Ireg1 and MTP1), the 
product of the Slc40a1 gene, was independently identified by three groups, using different  
approaches (Abboud & Haile, 2000; Donovan et al, 2000; McKie et al., 2000) and has been 
reported to be expressed and to play a critical role in several different tissue involved in 
mammalian iron homeostasis, including duodenal enterocytes (iron uptake and export into 
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the circulation; hepatocytes (storage); syncytiotrophoblasts (transfer to embryo) and 
reticuloendothelial macrophages (iron recycling from senescent red blood cells). FPN1 
appears to act as an iron exporter (Donovan et al., 2000; McKie et al., 2000) and to be 
specifically regulated according to body iron requirements (Donovan et al., 2000; Martini et 
al., 2002; McKie & Barlow, 2004; Mok et al., 2004; Pietrangelo et al., 2004; Yang et al., 2002;  
Zoller et al., 2001) in these tissues. The FPN1 gene has been highly conserved during 
evolution and encodes for a protein composed of 571 aminoacids with a predict mass of 62 
kDa (for review see Cianetti et al., 2010).The presence of a well-conserved IRE in the 5’-UTR 
of FPN1 mRNA indicated the possibility of post-transcriptional control through the IRP-IRE 
systems (Donovan et al., 2000; Liu et al, 2002; Lymboussaki et al., 2003; McKie & Barlow, 
2004) but several recent observation have indicated a more complex regulation  of FPN1 
expression by iron (Cianetti et al., 2010). Hemochromatosis associated with mutations in 
FPN1 can result in two different types of iron loading: one type is phenotypically 
indistinguishable from classical HFE hemochromatosis (or hemochromatosis type 1) 
(Spelling), in that the patients have both an elevated transferrin saturation and serum 
ferritin, while the other type termed “ferroportin disease” is associated with microcytic 
anemia, a raised serum ferritin and iron deposition in macrophages rather than hepatocytes 
(Pietrangelo, 2004). FPN1 mutations have two effects, either causing misfolding of the 
protein and failure to reach the cell surface (“loss of function”)(Schimanski, 2005), or the 
mutant protein is expressed at the cell surface but is not inhibited by hepcidin (“loss of 
regulation”)(Drakesmith, 2005). Briefly it was shown that A77D, V162del, and G490D 
mutations, that are associated with typical pattern of disease in vivo, cause a loss of iron 
export function in vitro, but do not physically or functionally impede wild-type FPN1 
(Drakesmith, 2005; Schimanski, 2005). These mutations may, therefore, lead to disease by 
haploinsufficieny. By contrast the Y64N, N144D, Q248H and C326Y mutations, which can be 
associated with greater transferrin saturation and more prominent iron deposition in liver 
parenchyma in vivo, retained iron export function in vitro (Drakesmith, 2005; Schimanski, 
2005). Because the peptide hormone hepcidin inhibits ferroportin as part of a homeostatic 
negative feedback loop, it was postulated that this group of mutations may resist inhibition 
to hepcidin resulting in a permanently “turned on” iron exporter (Drakesmith, 2005; 
Schimanski, 2005). All these results with A77D, V162del and G490D mutations of FPN1 are 
consistent with the scheme proposed by Montosi et al (Montosi et al., 2001)) to explain the 
macrophage iron loading observed in patients with these mutations (Schimanski et al., 
2005): lower serum iron resulting from iron sequestration in macrophages reduces 
availability to the bone marrow for erythropoiesis thus leading to anemia that was 
effectively observed in some patients with mild anemia in the early stages of disease and 
that respond poorly to phlebotomy (Pietrangelo,2004; Schimanski et al, 2005). So iron 
overload may be a consequence of the erythron signalling to the gut enterocyte to increase 
iron uptake from the diet to compensate for the anemia.  According to recent progress in 
this field it is likely that the erythron signalling is directly working through hepcidin-
ferroportin interaction. By contrast the Y64N, N144D, Q248H and C326Y mutations, which 
can be associated with greater transferrin saturation and more prominent iron deposition in 
liver parenchyma in vivo, retain iron export function in vitro (Schimanski et al., 2005; 
Drakesmith et al., 2005). It was postulated that this group of mutations may resist inhibition 
by hepcidin, so interfering with its homeostatic negative feedback loop and resulting in a 
permanently “turned on” iron exporter (Schimanski et al., 2005; Drakesmith et al., 2005). 
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8. Ineffective erythropoiesis and thalassemia 
In recent years there has been important advancement in our understanding of iron 
metabolism, mainly as a result of the discovery of hepcidin , a key regulator of whole-body 
iron homeostasis (for an exhaustive review see Ganz& Nemeth, 2006; Piperno et al, 2009; 
Lee & Beutler, 2009). Increasing experimental evidence suggested that a single molecule 
could be the “stores”, the “erythropoietic” and the “inflammation” regulator of iron 
absorption and recycling [Cianetti et al., 2010; Fleming & sly, 2001; Nicolas et al., 2002), and 
that hepcidin acted principally or solely by binding to ferroportin, the only known cellular 
iron exporter, causing ferroportin to be phosphorylated, internalized, ubiquitylated, sorted 
(Nemeth et al., 2004) through the multivesicular body pathway and degraded in lysosomes 
(Ganz, 2005; Nemeth et al., 2004). Different stimuli can modulate hepcidin and act as 
positive or negative regulators. Four major regulatory pathways (erythroid, iron store, 
inflammatory and hypoxia-mediated regulation) that act through different signaling 
pathways to control the production of hepcidin are known (Cianetti et al., 2010). It is 
obvious that this complex network of interactions must be subjected to very close control in 
order to ensure that the iron erythropoietic demand is met and, in turn, adequate 
concentrations of iron in the circulation are always present (Cianetti et al., 2010; Piperno et 
al., 2009). Under normal conditions iron store and inflammatory regulation activate 
hepcidin transcription in the hepatocytes through the bone morphogenetic proteins 
(BMPs)/SMAD4 and signal transducer and activator of transcription-3 (STAT-3) pathways, 
respectively (Andrews, 2008; Piperno et al., 2009). The hemochromatosis protein HFE, 
transferrin receptor 2 (TfR2) and the membrane isoform of hemojuvelin (mHJV) are all 
positive modulators of hepcidin transcription and when defective, lead to hemochromatosis 
(HH) in humans (De Domenico et al., 2008; Piperno et al., 2009). Oppositely, hypoxia, 
anemia, increased erythropoiesis and reduced iron stores all negatively regulate hepcidin 
expression(Piperno et al., 2009). Emerging evidence suggests that erythropoiesis modulates 
hepcidin expression, with increased erythropoietic activity suppressing the action of 
hepcidin (Dallalio et al., 2006; Dunn et al., 2007; Kattamis et al., 2006; Pak et al., 2006; 
Vokurka et al., 2006). This in turn facilitates export of iron from the reticuloendothelial 
system and enterocytes, increasing the availability of iron for erythropoiesis (Dunn et al., 
2007; Pak et al., 2006). Anemia and hypoxia also suppress hepcidin expression, although 
recent experiments indicate that functional erythropoiesis is required (Dunn et al., 2007; Pak 
et al., 2006; Vokurka et al., 2006) for these conditions to regulate hepcidin expression. Finally 
it is evident that erythropoiesis and iron metabolism are extremely intertwined in that 
alteration of one of the two may have a major impact on the second (Gardenghi et al., 2007; 
El Rassi et al., 2008; Rivella, 2009; Rund & Rachmilewitz, 2005; Weatherall & Clegg. 2001; 
Weatherall, 2001). That’s the reason why thalassemia intermedia and thalassemia major are 
the best studied human models of hepcidin modulation by ineffective erythropoiesis. Beta-
thalassemias are caused by mutations in the beta-globin gene resulting in reduced or absent 
beta-chain synthesis (for exhaustive reviews see Wetherall, 1998; Olivieri, 1999; Cao & 
Galanello, 2010; Ginzburg & Rivella, 2011). A relative excess of ǂ-globin chain synthesis 
leads to increased erythroid precursor apoptosis, causing ineffective erythropoiesis which 
together with extramedullary expansion, splenomegalia and shortened red blood cells 
survival result in anemia (Huihui & Ginzburg, 2010). Patients either homozygous or 
compound heterozygous for mutation in the ǃ-globin gene present with a broad range of 
clinical severity due to genotypically different mutations, combination inheritance with 
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hemoglobinopathies, and additional modifying factors (Ginzburg & Rivella, 2011; Huihui & 
Ginzburg, 2010). Individuals with thalassemia major require regular red blood cell (RBC) 
transfusions to ameliorate anemia and suppress extramedullary erythropoiesis. Patients 
with beta-thalassemia intermedia show a milder clinical picture with more beta-globin 
chains synthesis and require only intermittent transfusions (Huihui & Ginzburg, 2010). 
Patients with beta-thalassemia have increased intestinal iron absorption which, in addition 
to transfusion dependence, contributes to iron overload (Huihui & Ginzburg, 2010). 
Progressive iron overload is the most salient and ultimately fatal complication of beta-
thalassemia. Iron deposition occurs in visceral organs (mainly in the heart, liver and 
endocrine glands), causing tissue damage and ultimately organ dysfunction and failure 
(Fig.2). Both transfusional iron overload and excess gastrointestinal absorption are 
contributory. Paradoxically, excess gastrointestinal iron absorption persists despite massive 
increases in total body iron load (Fleming & Sly, 2001; Gardenghi et al., 2007; Rivella, 
2009)(Fig.3). However, little is known about the relationship among ineffective 
erythropoiesis, the role of iron-regulatory genes, and tissue iron distribution in beta-
thalassemia. If iron were a dominant regulator, patients with beta-thalassemia should 
express very high levels of hepcidin in serum; in contrast, the levels are very low, suggesting 
that the ineffective erythropoiesis alone is able to suppress the synthesis of hepcidin in spite 
of the presence of a severe iron overload (Cianetti et al, 2010; Piperno et al., 2009). 
Furthermore, serum from patients with thalassemia inhibited hepcidin mRNA expression in 
the HepG2 cell line, which suggested the presence of a humoral factor that down-regulates 
hepcidin (Weizer-Stern et al., 2006). The nature of the erythropoietic regulator of hepcidin is 
still uncharacterized, but may include one or more proteins during active erythropoiesis. 
Recent observations in thalassemia patients has suggested that one of these regulators could 
be the cytokine growth differentiation factor-15 (GDF15) (Piperno et al., 2009; Tanno et al., 
2007). GDF15 is a divergent member of the transforming growth factor-beta superfamily 
that is secreted by erythroid precursors and other tissues. It has been identified as an 
oxygen-regulated transcript responding to hypoxia and as a molecule involved in hepcidin 
regulation (Cianetti et al., 2010; Bottner et al., 1999; De Caestecker, 2004; Tanno et al., 2007). 
Serum from thalassemia patients suppressed hepcidin mRNA expression in primary human 
hepatocytes and depletion of GDF15 reversed the hepcidin suppression (Piperno et al., 2009; 
Tanno et al., 2007). It was suggested that GDF15 overexpression arising from an expanded 
erythroid compartment contributed to iron overload in thalassemia syndromes by inhibiting 
hepcidin expression, possibly by antagonizing the BMP pathway. Without going into a 
detailed analysis of the GDF15 regulation mechanisms, we would like to recall the results 
obtained recently, that are in our view important to start reflecting on the existence of 
alternative ways that regulate hepcidin production (Cianetti et al., 2010). Recently a very 
interesting study demonstrated that expression of both GDF15 mRNA and protein was 
strongly and specifically responsive to intracellular iron depletion in a number of human 
cell lines and in vivo in humans (Lakhal et al., 2009; Cianetti et al., 2010). This up-regulation 
is independent of IRP1, IRP2 and the HIF pathway suggesting the involvement of a novel 
iron-regulatory pathway (Lakhal et al., 2009). This study showed that GDF15 was induced 
by over-expression of wild type ferroportin (Lakhal et al., 2009). This observation is very 
intriguing because it connects the iron-mediated regulation of GDF15 concentration to 
patho-physiological levels of iron: despite systemic iron overload, ineffective erythropoiesis 
and associated iron-fluxes in beta-thalassemia might generate an iron deficiency signal in a 
relevant molecular or cellular context and consequent stimulation of GDF15 expression in a 
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particular erythroid compartment (Cianetti et al., 2010; Lakhal et al., 2009). Recent literatures 
provided at least two more molecules potentially involved in the regulation of hepcidin by 
erythropoiesis, i.e. the human twisted gastrulation factor (TWSG1) (Tanno et al., 2009) and 
the Oncostatin M (OsM) (Chung et al., 2010; Kanda et al., 2009). In contrast to GDF15, the 
highest-level expression of TWSG1 was detected at early stages of erythroblast 
differentiation before hemoglobinization of the cells (Tanno et al.,2009). In human cells, 
TWSG1 suppressed hepcidin through a BMP-dependent mechanism (Tanno et al., 2009). In 
vivo studies on thalassemic mice showed that TWSG1 expression was significantly 
increased in the spleen, bone marrow and liver. So it was proposed that TWSG1 might act 
with GDF15 to dysregulate iron homeostasis in beta-thalassemia (Tanno et al., 2009). In 
contrast to GDF15 and TWSG1, recent observations have showed that OsM could induce 
hepcidin expression in human hepatoma cell lines mainly through the JAK/STAT pathways 
(Kanda et al., 2009). Finally, results obtained by HuH7 hepatoma cells cocultured  with 
primary human erythroblasts or erythroleukemic UT7 cells presented a 20- to 35-fold 
increase of hepcidin expression and identified OsM as responsible for increased levels of 
hepcidin (Chung et al., 2010). Furthermore, this study described the biological involvement 
of OsM in iron metabolism “in vivo” through direct transcriptional regulation of hepcidin 
gene expression and suggested a new OsM-hepcidin axis that might be critical in the 
development of hypoferremia in inflammation (Chung et al., 2010). 
 
Fig. 2. A summary of the causes of iron overload. A schematic representation of the main 
causes of severe iron overload and  its most important clinical manifestations. 
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Fig. 3. Pathophysiology of beta-thalassemia and corresponding clinical manifestations.  
A summary of the effects of excess production of free alpha-globin chains. Excess unbound 
alpha-globin chains and their degradation products precipitate in red-cell precursors, 
causing defective maturation and ineffective erythropoiesis. 
9. Ferroportin and erythroid cells 
We reported for the first time the expression of FPN1 mRNA and protein in normal human 
erythroid cells at all stages of differentiation (Cianetti et al., 2005). The presence of an iron 
exporter was very surprising because the erythroid cells need to incorporate very high 
amounts of iron to support the continued synthesis of heme and hemoglobin (Cianetti et al., 
2010). The IRE element in the 5’-UTR of FPN1 mRNA was demonstrated to be functional in 
erythroid cells and able to mediate translational modulation by cellular iron levels (Cianetti 
et al., 2005). Nonetheless, FPN1 protein expression appeared to maintain a constant level 
during different steps of erythroid differentiation and after iron treatments (Cianetti et al., 
2005). A solution to this problem could be to use an upstream alternative promoters to 
produce mRNA species in which the 5’-UTR IRE could be spliced out or made non-
functional (Cianetti et al., 2010). We described for the first time the existence of two 
alternative FPN1 transcripts (variant II and III), other than the IRE-containing canonical one 
(variant I), that did not contain the IRE element in their 5’-UT region, did not respond to iron 
treatments and together accounted for more than half of total FPN1 mRNA present in 
erythroid cells (Cianetti et al., 2005; Cianetti et al., 2010). These transcripts arise from the 
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usage of alternative upstream promoters and differential splicing of 5’-UTR sequences. 
Interestingly, these transcripts were expressed mainly during the middle steps (4-11 days) of 
in vitro erythroid differentiation, corresponding to the maturation from late erythroid 
progenitors to polychromatophilic erythroblasts (Cianetti et al., 2005) (Fig.1). At these stages 
of erythroid differentiation TfR1, the receptor responsible for iron import in erythroid cells, 
is strongly and increasingly expressed (Sposi et al., 2000). Therefore, the non-IRE (variant II 
and III) FPN1 transcripts were expressed when erythroid progenitor/precursor cells need to 
accumulate iron into the cells (Cianetti et al.,2005). It was speculated that expression of the 
non-IRE FPN1 transcripts could produce a constant level of the transporter, unresponsive to 
the very high iron levels present in maturing erythroid cell. In contrast, IRE-containing 
FPN1 transcripts were mainly expressed in undifferentiated erythroid progenitors and in 
mature terminal erythroblasts, suggesting a possible role at these particular stages of 
erythroid differentiation (Cianetti et al., 2005; Cianetti et al., 2010). The existence of multiple 
FPN1 alternative transcripts indicated a complex regulation of the FPN1 gene in erythroid 
cells and the possibility that the control of FPN1 expression by iron conditions in different 
cell types might be complex. So in erythroid cells the regulation of FPN1 mRNA translation 
through the 5’-UTR IRE mechanism might be silenced because in this cell type a high level 
of iron uptake is needed to accumulate high amounts of iron required for optimal heme 
synthesis (Cianetti et al., 2005). A solution for this problem might be the utilization of an 
upstream alternative promoter to produce mRNA species in which the 5’-UTR IRE might be 
spliced out or made non functional (Cianetti et al., 2005; Cianetti et al., 2010). The alternative 
FPN1 transcripts are differentially expressed during erythroid differentiation, in particular 
indicating a sequential and specific activation pathway, with an apparently mutual 
exclusion between variant I IRE and variant II/III not containing the IRE transcripts (Cianetti 
et al., 2005) (Fig.1). These observations suggest that erythroid precursor cells need FPN1 
transcript without a IRE to evade translational control by IRP-IRE system in order to export 
iron during the critical period when cells are committed to proliferate and differentiate 
(Cianetti et al., 2010). Once the precursor erythroid cells begin to produce hemoglobin, FPN1 
without a IRE diminishes and FPN1 with a IRE predominates allowing erythroid cells to 
limit iron export through the IRP-IRE system and synthesize heme without developing 
microcytic anemia (Cianetti et al., 2010) (Fig.1).  
10. New potential therapeutic opportunities 
It is increasingly evident that the iron metabolism, heme and cellular erythropoiesis are 
inextricably linked, because iron metabolism (Andrews, 2005; Nemeth, 2008) and cellular 
heme (for exhaustive review see Tsiftsoglou et al., 2006) are two of the most relevant key 
regulators of erythropoiesis (Cianetti et al., 2010). The complex regulation of erythropoiesis 
suggests the existence of several molecular targets that could be exploited therapeutically 
for treatment of RBC disorders like thalassemias and anemias (Tsiftsoglou et al., 2009). We 
must differentiate between primary iron overload, and iron overload that accompanies 
ineffective erythropoiesis: in the latter case the administration of hepcidin might be 
considered as a new potential therapeutic approach to reduce iron overload in thalassemias 
and other forms of anemia associated with ineffective erythropoiesis (Cianetti et al., 2010; 
Tsiftsoglou et al., 2009). The reduced number or the absence of mature erythroid cells in 
beta-thalassemia patients is still very difficult to understand, and it has become one of the 
paradoxes among the most difficult to resolve : when the body has greater need for red 
blood cells instead it responds by decreasing their production (Rivella,2009). The most 
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probable hypothesis to explain this phenomenon might rely on the existence of intrinsic and 
extrinsic mechanisms that would affect the process of differentiation: for example in cells 
where the synthesis of beta-globin gene is defective to the point that they ensure a 
stoichiometric between alpha and beta globin chains, a security mechanism can block the 
intrinsic maturation or, alternatively, an amount of heme in excess can be an extrinsic signal 
to prevent the differentiation that would lead to clusters of alpha globin chains production 
of reactive oxygen species (ROS) too toxic to survive (Cianetti et al, 2010; Rivella, 2009). 
There is much experimental evidence that oxidative stress may limit the process of 
differentiation. All this of course worsens the anemic outline (Rivella, 2009). So the 
contribution of these mechanisms to ineffective erythropoiesis might be different in each 
patient according to level of beta-globin synthesis and other extrinsic factors such as iron 
overload (Rivella,2009). At this point the question arises: is there a meeting point between 
different signaling pathways, although activated by different signals? Recent discoveries 
indicate that there is a potential for therapeutic intervention in beta-thalassemia by means of 
manipulating iron metabolism (Mabaera et al., 2008; Rivella, 2009; Rund & Rachmilewitz, 
2005). A recent study suggested a link between EpoR/Jak/Stat signaling and iron 
metabolism, showing that in mice that completely lack Stat5 activity the cell surface levels of 
TfR1 on erythroid cells were decreased more than 2-fold (Kerenyi et al., 2008). Another 
study suggested a direct involvement of Epo in hepcidin regulation through the 
transcriptional factor C/EBP alpha (Pinto et al., 2008). In addition a link has been shown 
between Jak 2 and FPN1: Jak2 phosphorylates FPN1 following binding of this protein to 
hepcidin (De Domenico et al., 2009). Phosphorylation of FPN1 then triggers its 
internalization and degradation (De domenico et al., 2009). Therefore Jak2 might represent 
one of the major links at the interface between erythropoiesis and iron metabolism 
suggesting that use of Jak2 inhibitors, antioxidant, and analog of the hepcidin might be used 
to reduce ineffective erythropoiesis and abnormal iron absorption (Cianetti et al., 2010; 
Rivella, 2009). Administration of synthetic hepcidin or of agents that increase its expression, 
may be beneficial in controlling absorption of this metal (Piperno et al., 2009). Hepcidin 
agonists or stimulators of hepcidin production are being developed for the treatment or 
prevention of iron overload in hepcidin deficiency states, including hereditary 
hemochromatosis and beta-thalassemia (Ganz, 2011). In the mouse model of beta-
thalassemia, transgenic hepcidin therapy improved iron overload as well as erythropoiesis 
suggesting that hepcidin deficiency or iron overload may adversely impact erythropoiesis in 
this disease (Ganz.2011). Hepcidin antagonists and inhibitors of hepcidin production may 
find utility in the treatment of iron-restricted anemias, alone or in combination with 
erythropoiesis-stimulating agents (Ganz,2011).  Also GDF15 could be another potential 
therapeutic target for beta-thalassemia syndromes (Tanno et al., 2007). A major goal of 
hemoglobinopathy research is to develop treatments that correct the underlying molecular 
defects responsible for sickle cell disease and beta-thalassemia (Mabaera et al., 2008). One 
approach to achieving this goal is the pharmacologic induction of fetal hemoglobin (HbF). 
Although many of the events controlling the activity of the beta-globin locus are known, the 
details of those regulating normal human hemoglobin switching and reactivation of HbF in 
adult hematopoietic cells remain to be elucidated (Cianetti et al., 2010). If the molecular 
events in hemoglobin switching or gamma-globin gene reactivation were better understood 
and HbF could be fully reactivated in adult cells, the insights obtained might lead to a cure 
for these disorders (Cianetti et al., 2010). Agents that increase human HbF in patients may 
work at one or more levels: for example, hydroxyurea and 5-azacytidine kill dividing cells 
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preferentially and may increase gamma-globin expression indirectly through this effect [for 
complete reviews see Mabaera et al., 2008; Bank, 2006). Butyrate may work both by histone 
deacetylase (HDAC) inhibition and by increasing gamma-globin translation on ribosomes 
(Bank, 2006; Mabaera et al., 2008). The Stem Cell Factor (SCF) induced an “in vitro” 
expansion of effective erythropoiesis and a reactivation of gamma-globin synthesis up to 
fetal levels, paving the way to its potential use in the therapeutic treatment of this disease 
(Gabbianelli et al., 2008). Recently it was reported the ability of thalidomide to increase 
gamma-globin gene expression and the proportion of HbF-containing cells in a human in 
vitro erythroid differentiation system (Aerbajinai et al., 2007) showing that thalidomide 
induced production of ROS that in turn caused p38 MAPK phosphorylation and globally 
increased histone H4 acetylation (Aerbajinai et al., 2007; Mabaera et al., 2008). All these 
experiments present a body of evidence that suggests an important role for intracellular 
signaling in HbF induction (Cianetti et al., 2010). However, the mechanisms of action of 
these agents are not yet defined and their role in beta-thalassemia therapy is still being 
explored in light of its acceptable toxicity profiles adding to their promise as therapeutic 
agents (Ginzburg & Rivella, 2011). Key genes controlling fetal/adult globin switching have 
been identified (e.g. BCL11 and cMYB) and may ultimately serve as direct targets for small 
molecules that would increase HbF levels in this patients (Bauer & Orkin, 2011; Ginzburg & 
Rivella, 2011; Wilber et al., 2011).  Finally recent publications have demonstrated the 
importance of what has been termed the “integrated stress response” pathway in erythroid 
cells that is also activated from a variety of stress stimuli, including viral infection, NO, heat 
shock, ROS, endoplasmic reticulum stress, ultraviolet irradiation, proteosome inhibition, 
inadequate nutrients and, in erythroid cells, limiting amounts of heme (Chen, 2007; Cianetti 
et al., 2010; Mabaera et al., 2008 Wek et al., 2006).  
11. Conclusion 
Our understanding of the pathogenesis of iron-restricted anemias and iron-overload has 
been revolutionized by discovery of hepcidin and its role in iron homeostasis stimulating 
the development of new diagnostic and therapeutic modalities for these disorders. Further 
work is required to understand the mechanisms of hepcidin regulation by iron and 
erythroid activity and to understand the structure, the transport function and the complex 
regulation of the hepcidin receptor ferroportin. In conclusion we are increasingly convinced 
of the importance to study the molecular mechanisms of iron homeostasis dysregulation in 
thalassemia and in particular the GDF15-BMP-Hepcidin-Ferroportin regulatory way in 
order to understanding its contribute to iron overload. 
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